PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase

• Main Authors: Dahyun Park (Author), Sungho Bea (Author), Ji-Hwan Bae (Author), Hyesung Lee (Author), Young June Choe (Author), Ju-Young Shin (Author), Hoon Kim (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2024-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Aims Protein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are novel lipid-lowering agents used in patients with cardiovascular disease. Despite reassuring safety data from pivotal trials, increasing evidence from real-world studies suggests that PCSK9i increase the risk of bacteri...